Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 116 participants.

Also called NCT06101888

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06101888
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06101888. Allocation not applicable; no masking; primary purpose treatment. Start 2023-08-01 (actual); primary completion 2024-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
Condition
Aortic Regurgitation
Intervention (Device)
TaurusTrio™ Heart Valve System
Lead sponsor
Peijia Medical Technology (Suzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06101888
Content hash
a6421a5254b81bcaf103630094950c1fa65594091b4ddd0bd8a634d49a05e80f